Data from an ongoing Phase 2 clinical trial supported by Verona Pharma showed that seven days of treatment with ensifentrine using a pMDI (pressurized metered-dose inhaler) resulted in notable improvement in lung function in people with moderate to severe COPD. The trial demonstrated that ensifentrine administered by hand-held pMDI over one week provides clinically meaningful dose-dependent bronchodilation. Ensifentrine (RPL554) is an experimental therapy that works by blocking the activity of the enzymes phosphodiesterase 3 and 4. This in turn supports widening of the lungs’ airways.